Startseite » Aktuelles » Pressemitteilungen » Innovative Medicines Initiative Launches Translational Safety Biomarker Pipeline

Innovative Medicines Initiative Launches Translational Safety Biomarker Pipeline

15.04.2019 -

The Innovative Medicines Initiative (IMI) today announced the launch of the Translational Safety Biomarker Pipeline (TransBioLine) Project, a five-year program to generate exploratory and confirmatory data supporting regulatory qualification and acceptance of novel safety biomarkers for five target organ systems (kidney, liver, pancreas, vascular and central nervous system) for application in drug development. The contributions of KUM are coordinated by Prof. A Gerbes.